ImmuCell Corporation (ICCC) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
44/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinICCC / S&P 58.77% / 15.20% |
LoseICCC / S&P 8.49% / 15.00% |
LoseICCC / S&P -66.67% / 50.40% |
| 2026-Q12/3 |
WinICCC / S&P 2.93% / -4.33% |
LoseICCC / S&P 9.64% / 11.30% |
WinICCC / S&P 40.00% / 27.70% |
| 2025-Q40/3 |
LoseICCC / S&P -1.60% / 2.65% |
LoseICCC / S&P 4.34% / 9.00% |
LoseICCC / S&P -55.56% / 13.40% |
| 2025-Q31/3 |
LoseICCC / S&P -10.20% / 8.12% |
WinICCC / S&P 48.17% / 4.61% |
LoseICCC / S&P -156.00% / 13.45% |
| 2025-Q22/3 |
WinICCC / S&P 45.30% / 10.94% |
WinICCC / S&P 55.98% / 4.83% |
LoseICCC / S&P -139.62% / 10.63% |
| 2025-Q11/3 |
LoseICCC / S&P -6.99% / -4.27% |
WinICCC / S&P 68.67% / 4.98% |
LoseICCC / S&P -90.20% / 10.57% |
| 2024-Q42/3 |
WinICCC / S&P 41.87% / 2.41% |
WinICCC / S&P 114.07% / 5.25% |
LoseICCC / S&P -64.00% / 6.15% |
| 2024-Q31/3 |
LoseICCC / S&P -25.15% / 5.89% |
WinICCC / S&P 15.08% / 5.89% |
LoseICCC / S&P -38.27% / 6.11% |
| 2024-Q21/3 |
LoseICCC / S&P -8.49% / 4.28% |
WinICCC / S&P 15.56% / 5.38% |
LoseICCC / S&P -31.17% / 5.12% |
| 2024-Q10/3 |
LoseICCC / S&P 4.13% / 10.56% |
LoseICCC / S&P 1.07% / 5.71% |
LoseICCC / S&P -25.00% / 5.59% |
| 2023-Q41/3 |
LoseICCC / S&P -4.68% / 11.69% |
LoseICCC / S&P -33.35% / 6.81% |
WinICCC / S&P 141.94% / 7.78% |
| 2023-Q32/3 |
WinICCC / S&P 6.80% / -3.27% |
LoseICCC / S&P -18.98% / 7.52% |
WinICCC / S&P 800.00% / -5.03% |
| 2023-Q20/3 |
LoseICCC / S&P -3.10% / 8.74% |
LoseICCC / S&P -23.31% / 9.50% |
LoseICCC / S&P -7800.00% / -8.57% |
| 2023-Q10/3 |
LoseICCC / S&P -15.41% / 7.50% |
LoseICCC / S&P -24.23% / 10.77% |
LoseICCC / S&P -666.67% / -15.69% |
| 2022-Q41/3 |
LoseICCC / S&P -18.45% / 7.56% |
LoseICCC / S&P -3.51% / 11.88% |
WinICCC / S&P 3000.00% / -17.99% |
| 2022-Q31/3 |
LoseICCC / S&P -13.92% / -4.88% |
WinICCC / S&P 14.58% / 13.47% |
LoseICCC / S&P -1000.00% / -1.41% |
| 2022-Q22/3 |
WinICCC / S&P -9.95% / -16.10% |
WinICCC / S&P 26.93% / 13.71% |
LoseICCC / S&P -120.00% / 11.04% |
| 2022-Q12/3 |
WinICCC / S&P 20.63% / -4.60% |
WinICCC / S&P 45.37% / 15.97% |
LoseICCC / S&P -166.67% / 42.23% |
| 2021-Q41/3 |
LoseICCC / S&P -14.53% / 11.03% |
WinICCC / S&P 25.43% / 15.00% |
LoseICCC / S&P -92.86% / 96.40% |
| 2021-Q31/3 |
LoseICCC / S&P -1.47% / 0.58% |
WinICCC / S&P 15.18% / 10.77% |
LoseICCC / S&P -104.76% / 69.42% |
| 2021-Q21/3 |
LoseICCC / S&P -1.45% / 8.55% |
WinICCC / S&P 11.30% / 6.58% |
LoseICCC / S&P -79.17% / 51.81% |
| 2021-Q12/3 |
WinICCC / S&P 62.02% / 6.17% |
WinICCC / S&P 2.22% / -1.06% |
LoseICCC / S&P -18.18% / 7.39% |
| 2020-Q42/3 |
LoseICCC / S&P 9.58% / 12.15% |
WinICCC / S&P 11.80% / -3.72% |
WinICCC / S&P -17.65% / -33.42% |
| 2020-Q32/3 |
WinICCC / S&P 14.80% / 8.93% |
WinICCC / S&P 16.91% / -2.04% |
LoseICCC / S&P -34.37% / -27.10% |
| 2020-Q23/3 |
WinICCC / S&P 24.80% / 20.54% |
WinICCC / S&P 18.57% / -0.46% |
WinICCC / S&P -20.00% / -27.11% |
| 2020-Q11/3 |
LoseICCC / S&P -26.41% / -19.60% |
WinICCC / S&P 13.64% / 3.47% |
LoseICCC / S&P -38.89% / -14.75% |
| 2019-Q41/3 |
LoseICCC / S&P -7.54% / 9.07% |
WinICCC / S&P 24.91% / 5.36% |
LoseICCC / S&P -60.47% / 2.99% |
| 2019-Q32/3 |
LoseICCC / S&P -14.31% / 1.70% |
WinICCC / S&P 16.51% / 5.02% |
WinICCC / S&P 14.29% / 0.21% |
| 2019-Q21/3 |
LoseICCC / S&P 2.36% / 4.30% |
WinICCC / S&P 10.67% / 6.64% |
LoseICCC / S&P -0.00% / 8.65% |
| 2019-Q12/3 |
LoseICCC / S&P -9.93% / 13.65% |
WinICCC / S&P 28.12% / 8.12% |
WinICCC / S&P 80.00% / 14.29% |
| 2018-Q41/3 |
LoseICCC / S&P -15.37% / -13.52% |
LoseICCC / S&P 5.32% / 9.05% |
WinICCC / S&P 975.00% / 18.23% |
| 2018-Q31/3 |
WinICCC / S&P 22.14% / 7.71% |
LoseICCC / S&P ICCC unavailable / 10.21% |
LoseICCC / S&P -2900.00% / 19.06% |
| 2018-Q20/3 |
LoseICCC / S&P -2.57% / 3.43% |
LoseICCC / S&P ICCC unavailable / 9.03% |
LoseICCC / S&P -433.33% / 14.46% |
| 2018-Q10/3 |
LoseICCC / S&P -20.36% / -0.76% |
LoseICCC / S&P ICCC unavailable / 7.68% |
LoseICCC / S&P -242.86% / 12.46% |
| 2017-Q41/3 |
WinICCC / S&P 35.23% / 6.64% |
LoseICCC / S&P ICCC unavailable / 7.03% |
LoseICCC / S&P -130.77% / 13.82% |
| 2017-Q30/3 |
LoseICCC / S&P -11.32% / 4.48% |
LoseICCC / S&P ICCC unavailable / 5.68% |
LoseICCC / S&P -95.24% / 17.57% |
| 2017-Q21/3 |
WinICCC / S&P 32.55% / 3.09% |
LoseICCC / S&P ICCC unavailable / 4.83% |
LoseICCC / S&P -70.97% / 17.74% |
| 2017-Q10/3 |
LoseICCC / S&P -7.06% / 6.07% |
LoseICCC / S&P ICCC unavailable / 3.67% |
LoseICCC / S&P -58.82% / 13.32% |
| 2016-Q40/3 |
LoseICCC / S&P -23.03% / 3.82% |
LoseICCC / S&P ICCC unavailable / 2.09% |
LoseICCC / S&P -65.79% / 7.05% |
| 2016-Q31/3 |
WinICCC / S&P 12.03% / 3.85% |
LoseICCC / S&P ICCC unavailable / 0.20% |
LoseICCC / S&P -36.36% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ICCC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 56.56% | 20.78% |
| Annualized return | 56.56% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ICCC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 15.84% | 83.14% |
| Annualized return | 2.98% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ICCC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 37.64% | 319.30% |
| Annualized return | 3.25% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |